Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

@article{Sequist2007SecondgenerationEG,
  title={Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.},
  author={Lecia V Sequist},
  journal={The oncologist},
  year={2007},
  volume={12 3},
  pages={325-30}
}
Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising… CONTINUE READING